| Autor: |
Bernardeco, J., Cruz, J., Rijo, C., Cohen, A. |
| Předmět: |
|
| Zdroj: |
Ultrasound in Obstetrics & Gynecology; Oct2021 Supplement S1, Vol. 58, p222-222, 1p |
| Abstrakt: |
The best method of screening for Trisomy 21 (T21) is cell free fetal DNA (cffDNA), nevertheless, combined screening (including minor ultrasound markers) is broadly used either as the only screening test or as part of a contingent screening policy. Nasal bone (NB) is evaluated in the combined screening and it is also used in the 2nd trimester risk readjustment for T21, with one of the greatest positive likelihood ratios when it is an isolated finding. Logistic regression demonstrated that in case of an abnormal NB in the 1st trimester the odds ratio for an abnormal NB in the 2nd trimester is 18.926 (7.79-45.98; I p i -value < 0.01). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text